Skip to main content
OpenTrials
Completed

NCT Number: NCT02358798

Respiratory Function at Preschool Age of Children Detected of Cystic Fibrosis in Neonatal Period

The widespread neonatal detection of cystic fibrosis in France since 2002 permits to treat children from birth. New treatments used for young children involve to assess efficacy criteria specific to this population. Standard respiratory function criteria for older children and adults is forced expiratory volume/second.

This technique is not suited for preschool aged children (3 to 6 years old) because they are too old to be sedated and too young and immature to be able to make forced expiration technique that are correct, reproducible and prolonged during more than 1 second.

For preschool aged children, in order to assess distal damage and her consequence, the evaluations are: airway resistance by debit interruption technic (Rint), plethysmographic measure of specific resistance (sRaw), functional residual capacity by Helium dilution technique (CRF He), arterial blood gas measurement, pulmonary clearance index.

All these methods have a better success rate and can be used in alternative or with forced spirometry. However, each of them gives only a part of information on airway and lung damage of detected children. It is necessary to combine them for a better information on overall respiratory damage.

In France, each respiratory function test laboratory uses one or any of these methods in addition to flow-volume curve, in function of his practices and his equipment.

So, respiratory function test of preschool aged children is going to diversify more and more to the detriment of an homogeneity of practices between different centers.

A referent population during a longitudinal multicenter monitoring on large cohorts that describe the evolution of pulmonary function, obtained by a standardized methodology is necessary to assess the efficacy of any new treatment. And, with the homogenization of care of children detected of cystic fibrosis in different centers, the description of natural evolution of pulmonary function by a standardized methodology will improve the discriminative power of measure of respiratory function to assess the presence of a worsening in preschool-aged children.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital of Montpellier, Arnaud de Villeneuve

Montpellier, 34295, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient suffering from cystic fibrosis
  • Height between 90 et 130cm
  • No respiratory exacerbation since 4 weeks
  • Benefit from an insurance disease regime

Exclusion criteria

  • Law-protected patient
  • Patient's parent don't understand french language
  • Opposition to participation

Treatment and study plan

3 years-assessment of respiratory function

Other

Primary outcomes

  1. Time evolution of functional residual capacity by Helium dilution technique (CRF He)

    Time frame: at each four yearly routine visits

Secondary outcomes

  1. airway resistance by debit interruption technique (Rint)

    Time frame: at each four yearly routine visits

  2. plethysmographic measure of specific resistance (sRaw)

    Time frame: at each four yearly routine visits

  3. arterial blood gas measurement

    Time frame: at each four yearly routine visits

  4. pulmonary clearance index

    Time frame: at each four yearly routine visits

  5. flow-volume curve

    Time frame: at each four yearly routine visits

  6. measurement of organ damage

    Time frame: at each four yearly routine visits

  7. measurement of tobacco exposition

    Time frame: at each four yearly routine visits

  8. measure of administration antibiotics and antiasthmatics treatments

    Time frame: at each four yearly routine visits

    Comparison of the evolution of these parameters to changing those of a historical cohort evaluated before the introduction of neonatal screening.

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Acronym: REVOLMUCO

Important dates

Study start
2014
Primary completion
2020
Study completion
2020
First posted
Feb 9, 2015
Registry last updated
Apr 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.